Department of Medical Oncology, Mount Vernon Cancer Centre, London, U.K.
Department of Radiology, Paul Strickland Scanner Centre, London, U.K.
In Vivo. 2020 Nov-Dec;34(6):3675-3679. doi: 10.21873/invivo.12215.
BACKGROUND/AIM: High-dose chemotherapy (HDCT) and stem cell transplantation (SCT) have been established as the standard of care in patients with relapsed germ cell tumours (GCTs). We evaluated the safety, efficacy and tolerability of HDCT/ SCT in patients with relapsed GCTs.
Twenty-eight patients with relapsed GCTs, treated with HDCT, were included in this study. The conditioning regime was carboplatin, etoposide, cyclophosphamide and paclitaxel. Clinical, radiological imaging and tumour markers determined treatment outcomes.
Median age was 35 years (range=21-57 years) with 26 males and 2 females. Median time to first relapse was 6 months. Median time to progression after 2 line chemotherapy was 17.3 months. Fourteen patients hadMedian survival was 62 months and 16 patients (57%) are in clinical follow-up with surveillance.
In relapsed GCT patients, median survival may exceed 5 years post-HDCT and SCT.
背景/目的：高剂量化疗（HDCT）和干细胞移植（SCT）已被确立为复发性生殖细胞瘤（GCT）患者的标准治疗方法。我们评估了 HDCT/SCT 在复发性 GCT 患者中的安全性、疗效和耐受性。
本研究纳入了 28 例接受 HDCT 治疗的复发性 GCT 患者。预处理方案为卡铂、依托泊苷、环磷酰胺和紫杉醇。临床、影像学和肿瘤标志物确定了治疗结果。
中位年龄为 35 岁（范围=21-57 岁），男性 26 例，女性 2 例。首次复发的中位时间为 6 个月。二线化疗后进展的中位时间为 17.3 个月。14 例患者的中位总生存期为 62 个月，16 例（57%）患者正在进行临床随访和监测。
在复发性 GCT 患者中，HDCT 和 SCT 后中位总生存期可能超过 5 年。
